More articles from Volume 28, Issue 1, 2012
OrIGINaLNI radOVI OrIGINaL arTICLEs Reactive pleural effusion
OrIGINaLNI radOVI OrIGINaL arTICLEs Immunoexpression of Cathepsin D in primary and recidivant meningiomas
Ultrasonographic evaluation of simple ovarian cysts in postmenopausal women ristic r aleksandar, djukic Milan
Assessment of soil pollution in Belgrade
Nefarmakoloska kontrola bola u nespecificnom cervikalnom i lumbalnom sindromu
Article views
Savremena hirurška terapija karcinoma želuca
,
Dejan Stevanović
,
Nebojša Mitrović
,
Dragoš Stojanović
,
Damir Jasarović
,
Vladimir Špica
,
Ivan Pavlović
Milan Žegarac
Published: 01.12.2011.
Biochemistry
Volume 28, Issue 1 (2012)
pp. 432-444;
Abstract
Keywords
References
1.
Maruyama K. The most important prognostic factors for gastric cancer patients. a study using univariate and multivariate analysis. 1987;63–8.
2.
Noguchi Y, Imada T. radical suregery for gastric cancer.a review of the japanese expirience. Cancer. 1989;253–62.
3.
Ohiamax a. statistical evaluation of advacement in gastric cancer surgery with special reference to the significance of lymphadenectomy for cure. Word j.surgery. 1988;398–405.
4.
Iriyama K, Koike H. Is extensive lymphadenectomy necessery for surgical treatment of intramucosal carcinoma of the stomach ? arch of surgery. 1989;309–11.
5.
japanese research society Commitee on Phistopathological Classification for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology.Part II. jpn j surg. 1981;140–5.
6.
research society for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. Part I . Clinical klassifications. jpn j surg. 1981;127–239.
7.
Deng J, Liang H, Pan Y, Liu Y, Wang. Extended lymphadenectomy improvement of overall survival of gastric cancer patients with perigastric node metastasis. Langenbecks arch surg. 2011;(5):615–23.
8.
Wang Z, Jq C, Cao Y. systematic review of d2 lymphadenectomy versus d2 with para-aortic nodal dissection for advanced gastric cancer. World j Gastroenterol. 2010;(9):1138–49.
9.
Ielpo B, Buonomo E, O, Ld V, Petrella E, G, et al. Impact of number and site of lymph node invasion on survival of adenocarcinoma of esophagogastric junction. Interact Cardiovasc Thorac surg. 2010;(5):704–8.
10.
Putchakayala K, Difronzo L. d2 lymph node dissection improves staging inpatients with gastric adenocarcinoma. am surg. 2011;(10):1326–9.
11.
Saka M, Morita, Fukagawa T, Katai H. Present and future status of gastric cancer surgery. jpn j Clin Oncol. 2011;(3):307–13.
12.
2010;73–7.
13.
japanese Gastric Cancer association. japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;101–12.
14.
japanese Gastric Cancer association. japanese Gastric Cancer Treatment Guidelines 2010 (ver. 3). Gastric Cancer. 2011;113–23.
15.
Takeshi, Takashi. New japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;97–100.
16.
Hokita S. Extended gastric surgery: is paraaortic lymph node dissection essential for advanced gastric cancer. 1998;(4):498–503.
17.
Gong r, Wu H. do patients with pN0 gastric cancer benefit from prophylactic extended lymphadenectomy? surg Oncol. 2012;(1):7–11.
18.
Yiannakopoulou E, Gakiopoulou H. Clinical implications of the histologically and immunohistochemically detected solitary lymph node metastases in gastric cancer. scand j surg. 2011;(3):174–80.
19.
Walter B, Märkl B, Wagner T, Messmann M, H. Fulminant metastatic spread in a patient with an early gastric cancer. Endoscopy. 2009;(10):907–9.
20.
Lemmens V, Van Der Wurff Aa C, Jw, Bosscha K. Lymph node examination among patients with gastric cancer: variation between departments of pathology and prognostic impact of lymph node ratio. Eur j surg Oncol. 2011;(6):488–96.
21.
Pavlović I, Mitrović N, Vuković M. Importance of extensive lymphadenectomy in relation to the extent of metastatic lymph node involvement in patients with gastric carcinoma surgery. Med Pregl. 2003;(9–10):451–6.
22.
Roviello F, Pedrazzani C, Marrelli, Di Leo A, Caruso S, Giacopuzzi S, Corso G, De Manzoni G. super-extended (d3) lymphadenectomy in advanced gastric cancer. Eur j surg Oncol. 2010;(5):439–46.
23.
Wan Y, Pan Y, Liu Y, Wang Z. Ye j, Huang s. Lymph node metastasis and the extent of lymph node dissection for gastric cancer: report of 326 cases. Zhonghua Wai Ke Za Zhi. 2000;(10):752–5.
24.
Zilberstein B, Da C, Martins B, Jacob C, Bresciani C, Lopasso F. de Cleva r, Pinto junior PE, junior Ur, Perez rO, Gama-rodrigues j. Complications of gastrectomy with lymphadenectomy in gastric cancer. Gastric Cancer. 2004;(4):254–9.
25.
Persiani V, Biondi L, Greca A, Zoccali M, Ciccoritti L, Ugo. determinants of surgical morbidity in gastric cancer treatment. j am Coll surg. 2008;(1):13–9.
26.
Pavlović I, Mitrović N. Effect of systematic lymphadenectomy on postoperative mortality and morbidity in patients with gastric cancer. Med Pregl. 2004;(7–8):381–5.
27.
Inoue K, Nakane Y, Michiura T, Nakai K, Iiyama H, Sato M, et al. Histopathological grading does not affect survival after r0 surgery for gastric cancer. Eur j surg Oncol. 2002;(6):633–6.
28.
Br B, Günther F, Merkel, Horbach T, Hohenberger W, Günther K. d3 versus d2 dissection in stomach carcinoma. a case-control study of postoperative morbidity, survival and early oncologic outcome. Chirurg. 2002;(4):336–47.
29.
Kodera Y, Yamamura Y, Y. Peritoneal washing cytology. Prognostic value of positive findings in patients with gastric carcinoma undergoing a potencial curative resection. j surg Oncol. 1999;(2):60–4.
30.
Zhang H, Liu C, Wu D, Meng Y, Lu P, Wang. does d3 surgery offer a better survival outcome compared to d1 surgery for gastric cancer? a result based on a hospital population of two decades as taking d2 surgery for reference. BMC Cancer. 2010;308.
31.
Koga, Kishimoto S. Clinical and pathologic evaluation of ratient recurrence of gastric cancer than 5 years prospectively. am j surg. 1978;317–22.
32.
Ohiamax a. statistical evaluation of advacement in gastric cancer surgery with special reference to the significance of lymphadenectomy for cure. Word j.surgery. 1988;398–405.
33.
Hirasawa T, Gotoda T, Miyata. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009;148–52.
34.
Huscher C, G. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. ann surg. 2005;2132–237.
35.
Kitano N, Fujii K. a randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. surgery. 2002;(1):306–11.
36.
Macdonald, Benedetti. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl j Med. 2001;725–30.
37.
Cunningham. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl j Med. 2006;11–20.
38.
Nakajima T, Kinoshita T, Nashimoto. randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br j surg. 2007;1468–76.
39.
Winter K, Gs O. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (rTOG9904): quality of combined modality 43. therapy and pathologic response. Clin Oncol. 2006;3953–8.
40.
Pyrho¨nen S, Kuitunen T, Nyandoto P. randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br j Cancer. 1995;587–91.
41.
Koizumi W, Narahara H, Hara T. randomized phase III study of s-1 alone versus s-1 cisplatin in the treatment for advanced gastric cancer (The sPIrITs trial): a phase III trial. Lancet Oncol. 2008;215–21.
42.
Boku N, Yamamoto K. Fluorouracil versus combination of irinotecan plus cisplatin versus s-1 in metastatic gastric cancer: a randomized phase3 study. Lancet Oncol 47. 2009;1063–9.
43.
Narahara H, Iishi H, Imamura H. randomized phase III study comparing the efficacy and safety of irinotecan plus s-1 with s-1 alone as first-line treatment for advanced gastric cancer. Gastric Cancer. 2011;72–80.
44.
Shirao K, Boku N, Yamada Y. randomized phase III study of 5-fluorouracil continuous infusion (5-FUci) versus methotrexate and 5-FU sequential (MF) in gastric cancer with peritoneal metastasis: jCOG 0106. Proc am soc Clin Oncol. 2009;4545.
45.
Yamaguchi M, T. adjuvant chemotherapy for gastric cancer with s-1, an oral fluoropyrimidine. N Engl j Med. 2007;1810–20.
46.
Mitrovic N, Ilic G. sentinel lymph node -role in the gastrointestinal malignancy. Materia medica septembar. 2010;(3):101–9.
47.
Mitrovic N, Pavlovic I. Clinical application of sentinel lymph node biopsy for staging, treatment and prognosis of colon and gastric cancer. Hepatogastroenterology. 2009;1606–11.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
